At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 22 enrolled
Drug / intervention
valoctocogene roxaparvovecbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3b, Single Arm, Open-Label Study to Evaluate the Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII, With Prophylactic Corticosteroids in Hemophilia A Patients
In Brief
A Phase 3 clinical trial evaluating valoctocogene roxaparvovec for Hemophilia A. Completed, enrolled 22 participants across 12 sites in 4 countries.
Detailed Summary
This Phase III clinical study will evaluate the safety and effectiveness of valoctocogene roxaparvovec in combination with prophylactic corticosteroids in patients with severe hemophilia A.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHemophilia A
CountriesAustralia, Brazil, Taiwan, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartDec 2020
Primary CompletionJan 2023
Study CompletionMay 2025
TodayJul 2026
First PostedMar 26, 2020
Enrollment StartDec 8, 2020
Primary CompletionJan 27, 2023
Study CompletionMay 8, 2025
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 6.3 years ago
Interventions
valoctocogene roxaparvovecbiological
Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A